BRIEF published on 12/13/2024 at 23:05, 1 year 3 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 3 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
BRIEF published on 11/11/2024 at 07:05, 1 year 4 months ago Relief Therapeutics rapporte des résultats positifs dans l'essai RLF-TD011 pour l'épidermolyse bulleuse THÉRAPEUTIQUE DE SECOURS RLF-TD011 Résultats Des Essais Cliniques Epidermolyse Bulleuse Diversité Du Microbiome
BRIEF published on 11/11/2024 at 07:05, 1 year 4 months ago Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
PRESS RELEASE published on 11/11/2024 at 07:00, 1 year 4 months ago Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/04/2024 at 07:05, 1 year 4 months ago Relief Therapeutics et Renexxion envisagent une fusion inversée Biotechnologie Valeur Actionnariale Soins De Santé Fusion Inversée Troubles Gastro-intestinaux
BRIEF published on 11/04/2024 at 07:05, 1 year 4 months ago Relief Therapeutics and Renexxion Consider Reverse Merger Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
PRESS RELEASE published on 11/04/2024 at 07:00, 1 year 4 months ago Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger Relief Therapeutics signs non-binding letter of intent with Renexxion for reverse merger, aiming to create a combined entity with an expanded therapeutic pipeline Biopharmaceutical Relief Therapeutics Therapeutic Pipeline Reverse Merger Renexxion
BRIEF published on 10/29/2024 at 07:05, 1 year 4 months ago Relief Therapeutics met en avant les résultats de l'étude PKU GOLIKE PKU GOLIKE THÉRAPEUTIQUE DE SECOURS Engagement Des Patients Phénylcétonurie Absorption Des Acides Aminés
BRIEF published on 10/29/2024 at 07:05, 1 year 4 months ago Relief Therapeutics Highlights PKU GOLIKE Findings Patient Engagement Relief Therapeutics PKU GOLIKE Phenylketonuria Amino Acid Absorption
Published on 03/26/2026 at 23:00, 3 hours 3 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 3 hours 58 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 4 hours 3 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 4 hours 3 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 5 hours 3 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 5 hours 15 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 6 hours 43 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 6 hours 54 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 6 hours 54 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 7 hours 46 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 7 hours 46 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 8 hours 3 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 8 hours 3 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité
